FGL2/Fibroleukin Antibody (6D9) - Azide and BSA Free

Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01]

Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - FGL2 monoclonal antibody (M01), clone 6D9. Analysis of FGL2 expression in PC-12.

Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01]

Western Blot: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - Analysis of FGL2 expression in transfected 293T cell line by FGL2 monoclonal antibody (M01), clone 6D9.Lane 1: FGL2 transfected lysate(50 KDa).Lane 2: Non-transfected lysate.

Immunoprecipitation: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01]

Immunoprecipitation: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - Analysis of FGL2 transfected lysate using anti-FGL2 monoclonal antibody and Protein A Magnetic Bead, and immunoblotted with FGL2 MaxPab rabbit polyclonal antibody.

ELISA: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01]

ELISA: FGL2/Fibroleukin Antibody (6D9) [H00010875-M01] - Detection limit for recombinant GST tagged FGL2 is approximately 0.1ng/ml as a capture antibody.

Flow Cytometry: FGL2/Fibroleukin Antibody (6D9) - Azide and BSA Free [H00010875-M01] -

Inhibition of Fgl2 signaling improves the antitumor effect of immune checkpoint inhibitors. (A–H) MC38 tumor cells were injected subcutaneously into C57BL/6 mice, the mice were administered 100 ug anti-FGL2 ( alpha FGL2) or IgG every 3 days after the tumor size reached 100 mm3. Tumor growth (A), survival of MC38 tumor-bearing mice (B, n=9–10), percentage of CD4+ and CD8+ T cells (C), MDSCs (D), absolute number of G-MDSC and M-MDSC cells (E), macrophages (F) and DCs (G) in tumors, Filipin III staining of MDSCs (H), n=5. (I–M) WT mice were subcutaneously injected with MC38 tumor cells. Tumor-bearing mice were injected with IgG, anti-Fgl2 ( alpha Fgl2), anti-PD-L1 ( alpha PD-L1), or a combination of ɑFGL2 and anti-PD-L1 ( alpha F+P). Tumor growth was monitored (I), and the percentages of CD8+ T cells (J), MDSCs (K), CD8+ T cells producing IFN-gamma (L) and GzmB (M) in the tumor tissues were analyzed by FCM (n=5). (N) Fgl2 promotes the generation and immune suppressive effects of MDSCs via cholesterol metabolism and XBP1 signaling. Data are expressed as mean+/-SD. *p<0.05; **p<0.01; ***p<0.001; ns, no significant difference, by two-tailed unpaired Student’s t-test (A, C–H), log-rank (Mantel-Cox) test (B), one-way or two-way analysis of variance with Sidak multiple comparisons test was used to evaluate statistical significance (I–M). FCM, flow cytometry; Fgl2, fibrinogen-like protein 2; G-MDSCs, granulocytic myeloid-derived suppressor cell; KO, knockout; MDSCs, myeloid-derived suppressor cells; M-MDSC, monocytic myeloid-derived suppressor cell; WT, wild-type. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38056898), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Flow Cytometry: FGL2/Fibroleukin Antibody (6D9) - Azide and BSA Free [H00010875-M01] -

Inhibition of Fgl2 signaling improves the antitumor effect of immune checkpoint inhibitors. (A–H) MC38 tumor cells were injected subcutaneously into C57BL/6 mice, the mice were administered 100 ug anti-FGL2 ( alpha FGL2) or IgG every 3 days after the tumor size reached 100 mm3. Tumor growth (A), survival of MC38 tumor-bearing mice (B, n=9–10), percentage of CD4+ and CD8+ T cells (C), MDSCs (D), absolute number of G-MDSC and M-MDSC cells (E), macrophages (F) and DCs (G) in tumors, Filipin III staining of MDSCs (H), n=5. (I–M) WT mice were subcutaneously injected with MC38 tumor cells. Tumor-bearing mice were injected with IgG, anti-Fgl2 ( alpha Fgl2), anti-PD-L1 ( alpha PD-L1), or a combination of ɑFGL2 and anti-PD-L1 ( alpha F+P). Tumor growth was monitored (I), and the percentages of CD8+ T cells (J), MDSCs (K), CD8+ T cells producing IFN-gamma (L) and GzmB (M) in the tumor tissues were analyzed by FCM (n=5). (N) Fgl2 promotes the generation and immune suppressive effects of MDSCs via cholesterol metabolism and XBP1 signaling. Data are expressed as mean+/-SD. *p<0.05; **p<0.01; ***p<0.001; ns, no significant difference, by two-tailed unpaired Student’s t-test (A, C–H), log-rank (Mantel-Cox) test (B), one-way or two-way analysis of variance with Sidak multiple comparisons test was used to evaluate statistical significance (I–M). FCM, flow cytometry; Fgl2, fibrinogen-like protein 2; G-MDSCs, granulocytic myeloid-derived suppressor cell; KO, knockout; MDSCs, myeloid-derived suppressor cells; M-MDSC, monocytic myeloid-derived suppressor cell; WT, wild-type. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38056898), licensed under a CC-BY license. Not internally tested by Novus Biologicals.